Novartis burnishes Zolgensma data in presymptomatic patients as Roche's Evrysdi continues eating away at the SMA pie
With sales slowing and Roche’s Evrysdi hot on its tail, Novartis’ Zolgensma for spinal muscular atrophy is seeking to build a stable of data in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
